WMT AG

General information
WMT AG
Waldhofer Str. 104
69123 Heidelberg, Baden-W├╝rttemberg
Germany

Contact person: Claus Kremoser, Chief Executive Officer
Company main phone: +49 (6221) 65282-0
Website:  https://wm-therapeutics.com/
Year founded:2020
Source of foundation:Independent foundation
Corporate description / mission:
WMT develops small molecules to treat late-stage solid cancers. The company targets the so-called Warburg metabolism, i.e. the high rate of glycolysis and lactate production that is adopted by late-stage tumors. Applying anti-Warburg Warheads (AWWs) dim down this specific form of cancer metabolism, thereby lowering the lactate in the tumor microenvironment. As a result, achieve inhibition of tumor growth as such as well as re-stimulation of the immune system against the solid tumor.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Immunotherapy
  • Small molecules
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:1
X